Edgewise Therapeutics Cash Per Share vs. Current Valuation

EWTX Stock  USD 32.08  0.10  0.31%   
Based on Edgewise Therapeutics' profitability indicators, Edgewise Therapeutics may not be well positioned to generate adequate gross income at this time. It has a very high odds of underperforming in December. Profitability indicators assess Edgewise Therapeutics' ability to earn profits and add value for shareholders.
 
Cash Per Share  
First Reported
2010-12-31
Previous Quarter
4.99646913
Current Value
5.1
Quarterly Volatility
4.0543183
 
Credit Downgrade
 
Yuan Drop
 
Covid
At this time, Edgewise Therapeutics' Ebt Per Ebit is fairly stable compared to the past year. Effective Tax Rate is likely to rise to 0.20 in 2024, whereas Book Value Per Share is likely to drop 2.56 in 2024.
For Edgewise Therapeutics profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Edgewise Therapeutics to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Edgewise Therapeutics utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Edgewise Therapeutics's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Edgewise Therapeutics over time as well as its relative position and ranking within its peers.
  
Check out Investing Opportunities.
For more information on how to buy Edgewise Stock please use our How to Invest in Edgewise Therapeutics guide.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Edgewise Therapeutics. If investors know Edgewise will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Edgewise Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(1.50)
Return On Assets
(0.22)
Return On Equity
(0.32)
The market value of Edgewise Therapeutics is measured differently than its book value, which is the value of Edgewise that is recorded on the company's balance sheet. Investors also form their own opinion of Edgewise Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Edgewise Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Edgewise Therapeutics' market value can be influenced by many factors that don't directly affect Edgewise Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Edgewise Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Edgewise Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Edgewise Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Edgewise Therapeutics Current Valuation vs. Cash Per Share Fundamental Analysis

Comparative valuation techniques use various fundamental indicators to help in determining Edgewise Therapeutics's current stock value. Our valuation model uses many indicators to compare Edgewise Therapeutics value to that of its competitors to determine the firm's financial worth.
Edgewise Therapeutics is rated # 2 in cash per share category among its peers. It is rated as one of the top companies in current valuation category among its peers reporting about  509,026,608  of Current Valuation per Cash Per Share. At this time, Edgewise Therapeutics' Cash Per Share is fairly stable compared to the past year. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Edgewise Therapeutics' earnings, one of the primary drivers of an investment's value.

Edgewise Current Valuation vs. Cash Per Share

Cash per Share is a ratio of current cash on hands or in the banks of the company to a total number of shares outstanding. It is used to determine a firm's liquidity and is a good indicator of the overall financial health of a company. Value investors often compare this ratio to the current stock quote, and if it exceeds the stock price they would invest in it.

Edgewise Therapeutics

Cash Per Share

 = 

Total Cash

Average Shares

 = 
4.99 X
Companies with high Cash per Share ratio will be considered as an attractive investment by most investors. In most industries if you can single out an equity instrument trading below its cash per share value, you have a bargain and should consider buying it. Finding the stocks traded below their cash value, therefore, can be a good starting point for investors using strategies based on fundamentals.
Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.

Edgewise Therapeutics

Enterprise Value

 = 

Market Cap + Debt

-

Cash

 = 
2.54 B
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.

Edgewise Current Valuation vs Competition

Edgewise Therapeutics is rated as one of the top companies in current valuation category among its peers. After adjusting for long-term liabilities, total market size of Health Care industry is currently estimated at about 3.07 Billion. Edgewise Therapeutics totals roughly 2.54 Billion in current valuation claiming about 83% of equities under Health Care industry.

Edgewise Therapeutics Profitability Projections

The most important aspect of a successful company is its ability to generate a profit. For investors in Edgewise Therapeutics, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Edgewise Therapeutics will eventually generate negative long term returns. The profitability progress is the general direction of Edgewise Therapeutics' change in net profit over the period of time. It can combine multiple indicators of Edgewise Therapeutics, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
Last ReportedProjected for Next Year
Accumulated Other Comprehensive Income99 K104 K
Net Interest Income14.2 M14.9 M
Interest Income14.2 M14.9 M
Operating Income-114.4 M-108.6 M
Net Loss-100.2 M-95.2 M
Income Before Tax-100.2 M-95.2 M
Total Other Income Expense Net14.2 M14.9 M
Net Loss-60.9 M-57.8 M
Net Loss-100.2 M-95.2 M
Income Tax Expense-3.6 M-3.4 M
Non Operating Income Net Other4.6 M2.4 M
Change To Netincome12.6 M13.2 M
Net Loss(1.57)(1.49)
Income Quality 0.92  0.95 
Net Income Per E B T 0.91  1.03 

Edgewise Profitability Driver Comparison

Profitability drivers are factors that can directly affect your investment outlook on Edgewise Therapeutics. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Edgewise Therapeutics position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Edgewise Therapeutics' important profitability drivers and their relationship over time.

Use Edgewise Therapeutics in pair-trading

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Edgewise Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Edgewise Therapeutics will appreciate offsetting losses from the drop in the long position's value.

Edgewise Therapeutics Pair Trading

Edgewise Therapeutics Pair Trading Analysis

The ability to find closely correlated positions to Edgewise Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Edgewise Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Edgewise Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Edgewise Therapeutics to buy it.
The correlation of Edgewise Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Edgewise Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Edgewise Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Edgewise Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching

Use Investing Themes to Complement your Edgewise Therapeutics position

In addition to having Edgewise Therapeutics in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Emerging Markets Funds Thematic Idea Now

Emerging Markets Funds
Emerging Markets Funds Theme
Fund or Etfs that invest in markets of developing countries. The Emerging Markets Funds theme has 43 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Emerging Markets Funds Theme or any other thematic opportunities.
View All  Next Launch

Additional Tools for Edgewise Stock Analysis

When running Edgewise Therapeutics' price analysis, check to measure Edgewise Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Edgewise Therapeutics is operating at the current time. Most of Edgewise Therapeutics' value examination focuses on studying past and present price action to predict the probability of Edgewise Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Edgewise Therapeutics' price. Additionally, you may evaluate how the addition of Edgewise Therapeutics to your portfolios can decrease your overall portfolio volatility.